L’actualité de Novigenix
Suivez toute l’actualité de Novigenix
Novigenix awarded EUR 1.8M in the groundbreaking BRECISE IHI Consortium to industrialize AI-powered liquid biopsy for prediction of immunotherapy response
Lausanne, Switzerland, March 31, 2025 – Novigenix, a leader in AI-driven precision liquid biopsy solutions, has been awarded EUR 1.8M through the new BRECISE IHI grant funded by the European Union (EU) research initiative focusing on revolutionizing cancer diagnostics, treatment, and monitoring through advanced multi-omics and artificial intelligence. The BRECISE consortium was launched last week in Madrid at its
New study reveals novel multi-omics approach with unprecedented treatment response prediction in metastatic urothelial cancer
Lausanne, Switzerland, March 11, 2025 - Novigenix, a leader in AI-driven healthcare solutions, has published a groundbreaking study showcasing the predictive power of its LITOSeek™ platform for immunotherapy response in metastatic urothelial cancer. The study titled, “Multimodal Integration of Blood RNA and ctDNA Reflects Response to Immunotherapy in Metastatic Urothelial Cancer” [link], has been published in JCI Insight. Metastatic
Breakthrough study reveals blood transcriptomic alternations for early detection of colorectal cancer
Lausanne, Switzerland, November 25, 2024 – Novigenix, a leader in AI-driven healthcare solutions, has published a new study marking a significant milestone in advancing early colorectal cancer (CRC) detection through innovative immune system profiling. The groundbreaking research, “Human blood cell transcriptomics unveils dynamic systemic immune modulation along colorectal cancer progression,” [link] has been published in the Journal for Immunotherapy of Cancer. Dr. Pedro Romero, Chief Medical
Understanding Tumor Immunology: How AI-powered blood RNA analysis could unlock immunotherapy prognoses
By Pedro Romero, Chief Medical & Scientific Officer of Novigenix - Identifying markers in body fluids via liquid biopsy holds great promise for detecting diseases (such as cancer) at early stages, following disease progression and population heterogeneity, and, importantly, predicting a response to therapy with minimal patient inconvenience. Liquid biopsy relies on easy access to a multitude of molecular
Prostate cancer breakthrough: Novigenix-led project receives €1.75M grant to improve patient outcomes using liquid biopsy technology
Lausanne, Switzerland, September 24, 2024 – Groundbreaking funding promises to revolutionize care for patients with advanced prostate cancer by addressing treatment resistance through innovative liquid biopsy technology. Novigenix, a leader in AI-driven healthcare solutions, has today announced the approval of a Eurostars grant for the MYeloid SIGNATUREs (MY-SIGNATURE) project. This prestigious grant, totaling a consortium budget of €1.75 million,
Novigenix unveils multimodal liquid biopsy approach at ESMO 2024, advancing precision medicine with AI-powered immune profiling
Lausanne, Switzerland, September 12, 2024 – Novigenix, an innovator in precision medicine and liquid biopsy technologies, will showcase its multimodal approach at the European Society for Medical Oncology (ESMO) 2024 conference. This is poised to revolutionize the landscape of oncology treatment and drug development. The new approach combines advanced immune profiling with cell-free DNA (cfDNA) analysis, providing a comprehensive view of the
L’actualité du web
Retrouvez des informations importantes relatives au cancer du côlon
Le dépistage du cancer colorectal devrait aller de soi à partir de 50ans
PRÉVENTION Le dépistage du cancer colorectal est volontaire - mais les médecins le recommandent fortement. Prof. Dr. med. Christoph Beglinger Specialist for Gastroenterology u. Internal Medicine Cancer Colorectal - Dépistage : il y a maintenant trois options pour la prévention. La Suisse est à la traîne dans le dépistage du cancer colorectal selon une comparaison internationale. Seuls 30% de la population de plus
Le Cancer du côlon peut-il être évité ?
Même si il n'y a aucun moyen sûr pour éviter le cancer du côlon, certains facteurs pourraient permettre de le prévenir et ainsi réduire le risque d'en développer un. Le dépistage fait partie des facteurs que vous contrôlez et qui vous aidera à réduire votre risque de développer un cancer colorectal. Plus il est dépisté tôt, mieux il se soigne. Le
Les symptômes associés au cancer colorectal
Le cancer du côlon évolue lentement et ne présente souvent pas de signes ou symptômes avant d’être à un stade plus avancé1. C'est pourquoi il est bien trop souvent détecté tardivement alors qu'une détection précoce augmente les chances de survie. Même si il ne faut pas attendre l'apparation des premiers symptômes pour se faire dépister, il est important de reconnaitre les